Warn about counterfeiting and commercialization of influenza vaccines

Warn about counterfeiting and commercialization of influenza vaccines

The Federal Commission for the Protection against Sanitary Risks, COFEPRIS, was notified by the company Sanofi Pasteur SA de CV, about the counterfeiting and commercialization of two products: Fluzone® Quadrivalent and Vaxigrip®

Photo: GettyImages

© Provided by UnoTV
Photo: GettyImages

About Fluzone® Quadrivalent

The pharmaceutical company stated that some batches were not manufactured or distributed by them, so its sale is irregular.

The batches marked as fake of the product Fluzone® Quadrivalent They are: EUH2174AC, EUH071AB and E0H071AB.

Fluzone®Quadrivalent es una inactivated quadrivalent vaccine for immunization against disease caused by influenza virus type A (H1N1 and H3N2) and subtypes B contained in the vaccine.

Currently this vaccine is in the process of analysis by COFEPRIS in order to carry out its sale and distribution in the Mexican market, therefore, Sanofi Pasteur SA de CV, has not distributed any batch of the referred product for sale in the national territory.

Gallery: If the flu vaccine does not stop the spread of the virus, what is it for? (Excelsior)

The Undersecretary of Prevention and Health Promotion, Hugo López-Gatell Ramírez, stressed that the influenza vaccine has great limitations in its use in real conditions.

Respect Vaxigrip®

COFEPRIS received reports on the marketing and application in hospitals, clinics and private coexistence centers, of the product Vaxigrip®ff suspension, product that is for exclusive use of the health sector, so that, must not be marketed or applied out of this, since its safety and efficacy are not guaranteed.


Private hospitals, pharmacies and points of sale are asked refrain from acquiring to market products for exclusive use of the health sector.

To the general population, in case of identifying any of the referred products, it is recommended do not acquire it and make a complaint.

  • Report any adverse reaction or discomfort related to the use or consumption of medications.

The Federal Commission will continue with surveillance actions to prevent products, companies or establishments from violating current health legislation and not posing a risk to the health of the population.


Please enter your comment!
Please enter your name here